Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nivolumab and Relatlimab in Resectable NSCLC
NCT04205552Phase 2Completed
- Sponsor
- Universitätsmedizin Essen
- Start
- Mar 2020
- Primary completion
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 3
01
Overview
A Phase 2 trial of nivolumab, relatlimab in non-small cell lung cancer (NSCLC), sponsored by Universitätsmedizin Essen. Started Mar 2020; status: completed.
02
Drugs
nivolumabrelatlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04205552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04205552.